Generated by AI
Mesoblast Ltd Sponsored ADR is a biotechnology company focused on developing regenerative medicine products and allogeneic, off-the-shelf cellular therapies. The company’s platform is built around mesenchymal lineage cell technology designed for use across severe inflammatory and immune-mediated conditions, as well as selected cardiovascular and spine-related disorders. Its current pipeline includes cell-based medicines intended for hospital and specialist care settings, reflecting a focus on complex diseases with limited treatment options. Mesoblast operates through research, development, and commercialization activities across multiple regions, including Australia, the United States, Singapore, and Switzerland. As an ADR, Mesoblast Ltd Sponsored ADR gives U.S. investors access to the company’s underlying ordinary shares while representing a global healthcare business centered on advanced cell therapy and regenerative medicine.
Website55 Collins Street
Melbourne, VIC, 3000
Australia
The latest articles about MESO.
Tech-heavy indices are sliding after concerns about stricter rules on AI data centres and chipmakers, yet many Australian businesses built and still run by their original founders are not priced on AI hype at all. These leaders often think in decades, not quarters, and keep meaningful skin in the game. This article highlights three founder-led Australian stocks from our screener that show how that long-term mindset can reshape both risk and reward. The three stocks highlighted here offer a...
Summary of Oct 29's posts. Generated by AI.
Summary of Jul 18's posts. Generated by AI.
Summary of Jul 18's posts. Generated by AI.
Investors talking about MESO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.